Reinforcing healthy behaviors: Is there a role for CGM? Katie Weinger Clinical Trials Report 22 May 2009 Pages: 183 - 184
ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks HoWon LeeAmgad N. MakaryusSamy I. McFarlane Clinical Trials Report 22 May 2009 Pages: 185 - 187
Insulin resistance versus β-cell dysfunction in the pathogenesis of type 2 diabetes Ele Ferrannini Current Reports / Diabetes / Invited Commentary 22 May 2009 Pages: 188 - 189
Pathophysiology of prediabetes Muhammad A. Abdul-GhaniRalph A. DeFronzo OriginalPaper 22 May 2009 Pages: 193 - 199
Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus Kenneth Cusi OriginalPaper 22 May 2009 Pages: 200 - 207
The role of FOXO in the regulation of metabolism Danielle N. GrossMin WanMorris J. Birnbaum OriginalPaper 22 May 2009 Pages: 208 - 214
Thiazolidinediones in prediabetes and early type 2 diabetes: What can be learned about that disease’s pathogenesis Jack L. Leahy OriginalPaper 22 May 2009 Pages: 215 - 220
Impact of surgical and nonsurgical weight loss on diabetes resolution and cardiovascular risk reduction Katherine E. Nori JanoszKerstyn C. ZalesinBarry A. Franklin OriginalPaper 22 May 2009 Pages: 223 - 228
Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials Amgad N. MakaryusPhilippe AkhrassSamy I. McFarlane OriginalPaper 22 May 2009 Pages: 229 - 237
Group visits in the management of diabetes and hypertension: Effect on glycemic and blood pressure control Lisel M. Loney-HutchinsonAlfrede D. ProvilusSamy I. McFarlane OriginalPaper 22 May 2009 Pages: 238 - 242
Glycemic control and cardiovascular disease in chronic kidney disease Suma DronovalliBasil O. BurneyGeorge L. Bakris OriginalPaper 22 May 2009 Pages: 243 - 248
Antidiabetic medications and weight gain: Implications for the practicing physician Samy I. McFarlane OriginalPaper 22 May 2009 Pages: 249 - 254